11.5 Treatment Considerations for Special Populations
Key Takeaways
Men with breast cancer are usually ER-positive; ASCO recommends tamoxifen as standard adjuvant endocrine therapy for men, and an aromatase inhibitor should be combined with a GnRH agonist if used.
During pregnancy, breast surgery is possible in any trimester and anthracycline-based chemotherapy can be given after the first trimester, but radiation, trastuzumab, and endocrine therapy are deferred until after delivery.
Sentinel lymph node mapping in pregnancy uses technetium-99m alone; isosulfan blue is avoided because of anaphylaxis risk, and methylene blue is avoided because of fetal risk.
The POSITIVE trial found that pausing adjuvant endocrine therapy after 18 to 30 months to attempt pregnancy did not increase short-term breast cancer events.
ASCO recommends a geriatric assessment for adults 65 and older receiving chemotherapy, and selected women 70 and older with small ER-positive, node-negative cancers may omit sentinel node biopsy.
Why One Plan Does Not Fit All
Standard breast cancer pathways were built mostly on trials of cisgender women aged 40 to 70. The CBCN exam expects nurses to recognize where men, sexual and gender minority patients, young adults, pregnant patients, and older adults need different information, drug choices, or support.
Men With Breast Cancer
- Biology: more than 90% of male breast cancers are ER-positive; HER2-positive and triple-negative cancers are less common.
- Surgery: total mastectomy is most common because men have little breast tissue, but breast conservation is possible. Sentinel node biopsy follows the same rules as in women.
- Endocrine therapy: ASCO's male breast cancer guideline recommends tamoxifen for 5 years (extended to 10 in high-risk disease) as adjuvant therapy. An aromatase inhibitor alone is not recommended, because in men it raises testicular estrogen production through feedback; if an AI is needed (for example after a clot on tamoxifen), it is combined with a GnRH agonist.
- Side effects in men: hot flashes, decreased libido, erectile dysfunction, weight gain, mood changes, and thrombosis. These drive discontinuation, so ask directly.
- Genetics: offer germline testing to every man with breast cancer; BRCA2 is the most common finding and affects daughters and sons.
- Psychosocial: men report isolation in "pink" settings, embarrassment, and lack of male-specific information. Use inclusive materials and connect them with male breast cancer peer support.
Gender and Sexual Minority Patients
Lesbian, gay, bisexual, transgender, queer, and other sexual and gender minority (SGM) patients face discrimination, fear of disclosure, and lower screening rates. Practical actions:
- Collect sexual orientation and gender identity (SOGI) information respectfully, use the patient's name and pronouns, and document chosen family and healthcare proxies.
- Transgender women with breast cancer who take estrogen: decisions about continuing, reducing, or stopping gender-affirming estrogen for ER-positive cancer are individualized with the patient, oncology, and the gender-affirming care team; stopping can cause significant distress.
- Transgender men on testosterone: testosterone can be aromatized to estrogen; teams weigh continuation, adding an aromatase inhibitor, or other adjustments. Chest surgery choices can support gender goals, such as flat closure without reconstruction.
- Offer surgical options that fit identity, including aesthetic flat closure, and avoid gendered assumptions in education materials.
Young Adults
Women under 40 more often have high-grade, triple-negative, or HER2-positive cancers and more often carry germline variants.
- Genetic testing for all (ASCO recommends offering BRCA testing to everyone diagnosed at 65 or younger).
- Fertility preservation referral before chemotherapy; oocyte or embryo cryopreservation with letrozole-based stimulation, and GnRH agonist ovarian protection as an adjunct.
- Ovarian function suppression with endocrine therapy for high-risk premenopausal HR-positive disease.
- Pregnancy after breast cancer: it does not appear to worsen outcomes. In the POSITIVE trial, women who paused endocrine therapy after 18 to 30 months to try to conceive had a 3-year breast cancer event rate (8.9%) similar to a matched external control (9.2%), and most became pregnant. They then resumed therapy to complete the planned duration.
- Contraception: nonhormonal methods, such as the copper IUD, are preferred.
- Life-stage issues: careers, finances, dating, young children, and body image; refer to young-adult support programs.
Pregnancy-Associated Breast Cancer
| Intervention | Safety in pregnancy |
|---|---|
| Surgery (mastectomy or lumpectomy) | Safe in any trimester with obstetric input |
| Sentinel node biopsy | Technetium-99m alone; avoid isosulfan blue (anaphylaxis) and methylene blue (fetal risk) |
| Anthracycline-based chemotherapy | Acceptable in the second and third trimesters; avoid in the first trimester |
| Taxanes | Increasingly used in the second and third trimesters |
| Radiation | Deferred until after delivery |
| Trastuzumab and pertuzumab | Contraindicated (oligohydramnios) |
| Tamoxifen and other endocrine therapy | Contraindicated (teratogenic) |
| G-CSF and standard antiemetics | Generally usable when indicated |
Chemotherapy is usually stopped about 3 weeks before planned delivery so that maternal and neonatal blood counts recover. Breastfeeding is avoided during chemotherapy, HER2 therapy, and endocrine therapy. Termination of pregnancy does not improve survival. Coordinate with maternal-fetal medicine, and support the patient's emotional needs as she faces cancer and new parenthood at once.
Older Adults
Age alone should not dictate treatment, but physiologic reserve, comorbidities, and goals do.
- Geriatric assessment: ASCO recommends it for adults 65 and older receiving chemotherapy. It covers function, falls, comorbidity, cognition, nutrition, mood, polypharmacy, and social support. Tools such as the CARG or CRASH score estimate chemotherapy toxicity risk.
- Axillary de-escalation: the Society of Surgical Oncology Choosing Wisely statement advises against routine sentinel node biopsy in women 70 and older with clinically node-negative, early-stage, HR-positive, HER2-negative cancer.
- Radiation omission: for women about 65 to 70 or older with small, node-negative, HR-positive cancers treated with lumpectomy and endocrine therapy, trials such as CALGB 9343 and PRIME II showed omitting radiation slightly increases local recurrence without affecting survival.
- Primary endocrine therapy may be offered to frail patients who cannot undergo surgery.
- Supportive needs: caregiver availability, transportation, hearing and vision, and bone health on aromatase inhibitors.
Nursing Summary by Population
| Population | Priority nursing actions |
|---|---|
| Men | Offer genetic testing; teach tamoxifen side effects; provide male-specific resources |
| Sexual and gender minority patients | Use SOGI data, names, and pronouns; involve chosen family; coordinate gender-affirming care decisions |
| Young adults | Fertility referral before chemotherapy; contraception; pregnancy planning; age-specific support |
| Pregnant patients | Maternal-fetal medicine coordination; safe drug choices by trimester; no trastuzumab, radiation, or endocrine therapy until after delivery |
| Older adults | Geriatric assessment; de-escalation options; polypharmacy and adherence review; caregiver planning |
Across all groups, avoid assumptions: ask what matters most to the patient and build the plan around it.
A 64-year-old man with stage II ER-positive, HER2-negative breast cancer asks why he was prescribed tamoxifen instead of the aromatase inhibitor his sister takes. What is the best explanation?
Tamoxifen is standard adjuvant endocrine therapy for men; an aromatase inhibitor alone does not adequately suppress estrogen in men and would need a GnRH agonist.
Aromatase inhibitors are only effective in premenopausal women.
Men cannot take any endocrine therapy after mastectomy.
Tamoxifen is chosen only because it is less expensive.
A patient who is 18 weeks pregnant has newly diagnosed HER2-positive, node-positive breast cancer. Which treatment component must be deferred until after delivery?
Modified radical mastectomy
Doxorubicin and cyclophosphamide chemotherapy
Sentinel node mapping with technetium-99m
Trastuzumab
An 82-year-old woman with a 1.1-cm, clinically node-negative, ER-positive, HER2-negative cancer plans lumpectomy and endocrine therapy. Which approach reflects Choosing Wisely guidance?
Mandatory axillary lymph node dissection
Routine sentinel node biopsy is not needed because the result is unlikely to change her treatment.
Preoperative PET/CT and bone scan
Dose-dense chemotherapy before surgery
Sections you finish are checked off in the contents.